VEA
CLDX icon

Virtus ETF Advisers’s Celldex Therapeutics CLDX Stock Holding History

Virtus ETF Advisers’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,688
Closed -$67.9K – 502
2024
Q4 		$67.9K Buy
2,688
+159
+6% +$4.32K 0.03% 397
2024
Q3 		$86K Buy
2,529
+44
+2% +$1.68K 0.04% 400
2024
Q2 		$92K Buy
2,485
+86
+4% +$3.25K 0.05% 351
2024
Q1 		$101K Sell
2,399
-162
-6% -$6.65K 0.05% 362
2023
Q4 		$102K Sell
2,561
-70
-3% -$2.06K 0.06% 350
2023
Q3 		$72.4K Sell
2,631
-261
-9% -$8.18K 0.04% 377
2023
Q2 		$98.1K Buy
2,892
+379
+15% +$12.8K 0.06% 394
2023
Q1 		$90.4K Sell
2,513
-967
-28% -$41.7K 0.05% 362
2022
Q4 		$155K Sell
3,480
-1,367
-28% -$48.8K 0.08% 336
2022
Q3 		$136K Buy
4,847
+31
+0.6% +$950 0.05% 367
2022
Q2 		$130K Buy
4,816
+685
+17% +$19.9K 0.05% 351
2022
Q1 		$141K Sell
4,131
-251
-6% -$8.02K 0.06% 234
2021
Q4 		$169K Sell
4,382
-3,483
-44% -$152K 0.06% 290
2021
Q3 		$425K Sell
7,865
-435
-5% -$20.4K 0.19% 164
2021
Q2 		$278K Sell
8,300
-8,164
-50% -$224K 0.11% 204
2021
Q1 		$339K Buy
16,464
+290
+2% +$6.66K 0.14% 214
2020
Q4 		$283K Buy
+16,174
New +$291K 0.12% 241
2018
Q2 		– Sell
-17,095
Closed -$597K – 264
2018
Q1 		$597K Buy
17,095
+9,164
+116% +$355K 0.52% 106
2017
Q4 		$338K Sell
7,931
-1,387
-15% -$59.4K 0.42% 104
2017
Q3 		$400K Buy
9,318
+852
+10% +$31.9K 0.05% 111
2017
Q2 		$314K Buy
8,466
+3,450
+69% +$153K 0.05% 114
2017
Q1 		$272K Buy
5,016
+481
+11% +$25K 0.05% 149
2016
Q4 		$241K Buy
4,535
+566
+14% +$32.2K 0.07% 153
2016
Q3 		$241K Hold
3,969
– – 0.12% 127
2016
Q2 		$261K Buy
3,969
+2,819
+245% +$179K 0.19% 81
2016
Q1 		$65K Buy
+1,150
New +$129K 0.09% 149

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Virtus ETF Advisers's CLDX Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Celldex Therapeutics (CLDX) in Q1 2025, closing a stake of 2,688 shares — an estimated $67.9K sold.

Virtus ETF Advisers first reported a position in CLDX in Q1 2016 and held it in 26 quarters. The position peaked at $597K in Q1 2018. 171 funds tracked by Wall St. Rank hold CLDX as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Celldex Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 2,688 Celldex Therapeutics shares in Q1 2025, an estimated $67.9K.
  • Virtus ETF Advisers first reported a position in Celldex Therapeutics in Q1 2016 and held it in 26 quarters.
  • Virtus ETF Advisers's Celldex Therapeutics position peaked at $597K in Q1 2018.
  • 171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.